PMID- 11465946
OWN - NLM
STAT- MEDLINE
DCOM- 20010823
LR  - 20041117
IS  - 1521-6616 (Print)
IS  - 1521-6616 (Linking)
VI  - 100
IP  - 2
DP  - 2001 Aug
TI  - Pemphigus vulgaris: the role of IL-1 and IL-1 receptor antagonist in pathogenesis 
      and effects of intravenous immunoglobulin on their production.
PG  - 172-80
AB  - Intravenous immunoglobulin (IVIG) is increasingly being used for the treatment of 
      autoimmune diseases. In the present report, the role of IVIG on in vivo and in 
      vitro production of IL-1 and IL-1 receptor antagonist (Ra) was studied in 
      patients with pemphigus vulgaris (PV). Serum samples from 20 untreated patients 
      with active PV prior to initiation of systemic therapy, 20 patients receiving 
      IVIG treatment, 20 patients in clinical remission after conventional therapy, and 
      20 normal human controls were studied to determine the serum levels of IL-1alpha, 
      IL-1beta, and IL-1Ra. The in vitro production of these cytokines was measured in 
      the culture supernatant of peripheral blood mononuclear cells (PBMC) from 10 PV 
      patients immediately before and after IVIG therapy and from age and sex-matched 
      10 healthy donors simultaneously. Elevated levels of IL-1alpha and IL-1beta were 
      detected (i) in the serum of untreated PV patients with active disease prior to 
      systemic therapy and (ii) before IVIG infusions in patients receiving IVIG 
      therapy. These increased levels are statistically significant when compared to 
      the levels in healthy controls (P < 0.01). A marked reduction of IL-1alpha and 
      IL-1beta was detected (i) in the serum of patients in prolonged clinical 
      remission and (ii) immediately after IVIG infusion in those patients on IVIG 
      therapy. Increased level of IL-1Ra was detected in PV patients in prolonged 
      clinical remission and after IVIG infusion in those receiving IVIG therapy. These 
      differences were statistically significant when compared to the levels in normal 
      controls and to the levels in the sera of patients with active disease (P < 0.01) 
      or just before the beginning of IVIG infusion (P < 0.01). Similar differences in 
      the levels of IL-1alpha, IL-1beta, and IL-1Ra were found in the culture 
      supernatant of PBMC isolated from the PV patients pre and post IVIG therapy. 
      These observations suggests that, compared to normal controls, patients with 
      active PV have reversed levels of IL-1alpha, IL-1beta, and IL-1Ra. IVIG therapy 
      may down-regulate production of IL-1alpha and IL-1beta and enhance production of 
      IL-1Ra, in vivo and in vitro. This might be one of the important mechanisms by 
      which IVIG produces its early therapeutic effects in pemphigus vulgaris.
CI  - Copyright 2001 Academic Press.
FAU - Bhol, K C
AU  - Bhol KC
AD  - Department of Oral Medicine and Diagnostic Sciences, Harvard School of Dental 
      Medicine, Boston, Massachusetts 02115, USA.
FAU - Desai, A
AU  - Desai A
FAU - Kumari, S
AU  - Kumari S
FAU - Colon, J E
AU  - Colon JE
FAU - Ahmed, A R
AU  - Ahmed AR
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Immunol
JT  - Clinical immunology (Orlando, Fla.)
JID - 100883537
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Interleukin-1)
RN  - 0 (Receptors, Interleukin-1)
SB  - IM
MH  - Humans
MH  - Immunoglobulins, Intravenous/therapeutic use
MH  - Interleukin-1/*immunology
MH  - Pemphigus/drug therapy/*etiology/*immunology
MH  - Receptors, Interleukin-1/antagonists & inhibitors/*immunology
EDAT- 2001/07/24 10:00
MHDA- 2001/08/24 10:01
CRDT- 2001/07/24 10:00
PHST- 2001/07/24 10:00 [pubmed]
PHST- 2001/08/24 10:01 [medline]
PHST- 2001/07/24 10:00 [entrez]
AID - S1521-6616(01)95061-2 [pii]
AID - 10.1006/clim.2001.5061 [doi]
PST - ppublish
SO  - Clin Immunol. 2001 Aug;100(2):172-80. doi: 10.1006/clim.2001.5061.